Cellular & Molecular Medicine PhD students John Ryniawec and Kelvin Pond have been selected as UA ARCS Foundation scholars for 2018-2019! This award consists of a $10,5000 cash scholarship, a $500 travel grant and full base tuition. Congratulations, John and Kelvin!
Congratulations to Gregory Rogers, PhD, who was recently awarded a 4 year, $1.2 million grant from the Nation Institute of General Medicine Sciences (NIGMS). His grant entitled “Inherent mechanism that govern centrosome function and duplication” focuses on dissecting evolutionarily conserved mechanisms that control the behaviors of centrosomes -- processes that, when dysfunctional, contribute to ciliopathy, birth defects and tumorigenesis.
Congratulations to CMM professor Henk Granzier, PhD, and the Granzier Lab, who were featured in an article for UA News! The article focuses on the Granzier Lab's discovery that titin regulates thick filament length in striated muscle. "Functionally and clinically, it is very important to regulate the thick filament precisely, otherwise muscles would not function well," said Dr. Granzier. "Biologists have always wondered what makes them so precisely structured." https://uanews.arizona.edu/story/introducing-titin-protein-rules-our-hea...
The Granzier Lab's findings were recently published in Nature Communications: https://www.nature.com/articles/s41467-017-01144-9
Congratulations to CMM Assistant Professor Casey Romanoski, PhD, as she was selected to showcase her lab's research at the 2017 American Society of Human Genetics meeting in Orlando, FL. The Romanoski Lab is using genetic differences between people's vascular cells to better define the cellular mechanisms that explain why some people are more prone to develop vascular diseases.
In recent study led by CMM Assistant Professor Noel Warfel, PhD, researchers identified PIM kinase expression as a novel mechanism of resistance to anti-angiogenic agents. Using models of prostate and colon cancer, they show that PIM is upregulated following treatment with anti-angiogenic therapies, which reduces the ability of these drugs to disrupt tumor vasculature. Moreover, combined inhibition of PIM and VEGF produces a synergistic anti-tumor response characterized by decreased proliferation, reduced tumor vasculature, and reduced metastasis. These findings, published in Clinical Cancer Research, show that targeting PIM kinase activity is a promising strategy to combat hypoxia-mediated therapeutic resistance. http://clincancerres.aacrjournals.org/content/early/2017/10/28/1078-0432.CCR-17-1318